Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TrkA/p75NTR neurotrophin receptor system is a dual-receptor complex composed of the high-affinity tropomyosin receptor kinase A (TrkA) and the p75 neurotrophin receptor (p75NTR), which together coordinate the cellular response to nerve growth factor (NGF) (NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570488/). TrkA is a receptor tyrosine kinase that, upon NGF binding, activates intracellular cascades such as the PI3K/Akt and MAPK/ERK pathways to promote neuronal survival, differentiation, and neurite outgrowth (PatSnap, https://patsnap.com). The p75NTR, a member of the tumor necrosis factor receptor superfamily, acts as a co-receptor that increases the affinity and specificity of TrkA for NGF, but it can also signal independently to trigger apoptosis or growth cone collapse, particularly when activated by pro-neurotrophins (Wikipedia, https://en.wikipedia.org/wiki/P75_neurotrophin_receptor). This receptor system is a significant therapeutic target in oncology, where NTRK1 gene fusions act as oncogenic drivers, and in chronic pain management, where NGF-mediated signaling contributes to peripheral and central sensitization (NIH, https://pubmed.ncbi.nlm.nih.gov/26372482/). Drugs targeting this system include selective TrkA inhibitors like larotrectinib and entrectinib for cancer, and anti-NGF monoclonal antibodies like tanezumab for chronic pain (NIH, https://pubmed.ncbi.nlm.nih.gov/31112321/). However, therapeutic intervention must balance clinical benefits against safety concerns, such as neurological side effects for kinase inhibitors and rapidly progressive osteoarthritis for anti-NGF therapies (NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254551/).
Inhibition of TrkA tyrosine kinase activity; Sequestration of NGF to prevent receptor binding; Modulation of p75NTR-mediated apoptotic or survival signaling.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tropomyosin receptor kinase A and p75 neurotrophin receptor (TrkA/p75NTR).